MedTrace Logo

An Observational Study to Evaluate Physical Activity, Bleeding Incidence and Health Related Quality of Life, in Participants With Haemophilia A Without Inhibitors Receiving Standard of Care Treatment

NCT04165135 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 103

Last updated 2024-07-12

Study results available
· View outcomes & findings →

Summary

This multicenter, non-interventional, prospective study will collect information about activity status, bleeds, health-related quality of life (HRQoL), health status, and safety in participants with moderate or severe haemophilia A without factor VIII (FVIII) inhibitors, who are being treated in accordance with normal clinical practice.

Conditions

  • Severe Hereditary Factor VIII Deficiency Disease Without Inhibitor
  • Moderate Hereditary Factor VIII Deficiency Disease Without Inhibitor
  • Haemophilia A

Interventions

DRUG

Standard of Care for Haemophilia A

There is no pre-determined studied medicinal product. Any treatment (including treatments started during the observational period) will be administered according to standard clinical practice, independently of participation in the current study, according to clinician's independent therapeutic decision.

Sponsors & Collaborators

Principal Investigators

  • Clinical Trials · Hoffmann-La Roche

Eligibility

Min Age
12 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-24
Primary Completion
2022-04-28
Completion
2022-04-28

Countries

  • Italy

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04165135 on ClinicalTrials.gov